S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$7.07
+0.6%
$8.85
$3.45
$10.83
$308.89M1.04420,816 shs32,850 shs
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$16.10
+2.7%
$17.65
$8.92
$24.50
$729.33M1.67400,235 shs167,769 shs
Cutera, Inc. stock logo
CUTR
Cutera
$2.13
-3.6%
$2.13
$1.28
$24.71
$42.47M1.661.73 million shs356,887 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$91.74
-0.1%
$82.88
$36.42
$99.63
$3.00B1.99676,830 shs291,580 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-2.50%-11.24%-8.46%-11.57%-29.77%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-4.97%-9.42%-9.47%-10.50%-21.17%
Cutera, Inc. stock logo
CUTR
Cutera
0.00%+44.44%+11.06%-34.03%-90.15%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%+2.10%+20.91%+15.80%+38.64%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%-98.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.5613 of 5 stars
3.53.00.00.02.52.50.6
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
1.6972 of 5 stars
3.51.00.00.02.02.50.6
Cutera, Inc. stock logo
CUTR
Cutera
1.2026 of 5 stars
3.31.00.00.01.91.70.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.8564 of 5 stars
2.41.00.00.02.02.50.6
ViewRay, Inc. stock logo
VRAY
ViewRay
1.5591 of 5 stars
3.00.00.04.40.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6750.87% Upside
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$23.4045.34% Upside
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$14.75592.49% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.86
Moderate Buy$102.0011.18% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
2.00
Hold$1.31∞ Upside

Current Analyst Ratings

Latest CUTR, VRAY, AXGN, TMDX, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
3/22/2024
Cutera, Inc. stock logo
CUTR
Cutera
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00
3/22/2024
Cutera, Inc. stock logo
CUTR
Cutera
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
3/6/2024
Cutera, Inc. stock logo
CUTR
Cutera
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
1/19/2024
AxoGen, Inc. stock logo
AXGN
AxoGen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.94N/AN/A$2.22 per share3.18
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$143.27M5.09N/AN/A$7.67 per share2.10
Cutera, Inc. stock logo
CUTR
Cutera
$212.37M0.20N/AN/A($8.01) per share-0.27
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M12.42$0.14 per share645.09$4.20 per share21.84
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.52N/AN/AN/A-13.66%-22.38%-11.24%5/14/2024 (Estimated)
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$1.52N/AN/AN/A-46.37%-13.36%-10.83%5/8/2024 (Estimated)
Cutera, Inc. stock logo
CUTR
Cutera
-$150.83M-$7.34N/AN/AN/A-68.87%N/A-34.04%5/14/2024 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.77N/A223.76N/A-10.36%-2.35%-0.60%5/6/2024 (Estimated)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A

Latest CUTR, VRAY, AXGN, TMDX, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Cutera, Inc. stock logo
CUTR
Cutera
-$1.20-$2.27-$1.07-$2.27$49.10 million$49.54 million
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
3/5/2024Q3 2023
Cutera, Inc. stock logo
CUTR
Cutera
N/A-$2.22-$2.22-$2.22N/A$46.48 million
2/29/2024Q4 2023
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.24-$0.22+$0.02-$0.14$32.70 million$32.73 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.06
2.86
1.83
Cutera, Inc. stock logo
CUTR
Cutera
N/A
3.17
2.44
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.70%
Cutera, Inc. stock logo
CUTR
Cutera
2.90%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.70%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.69 million40.54 millionOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
40945.30 million44.08 millionOptionable
Cutera, Inc. stock logo
CUTR
Cutera
54019.94 million19.37 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.71 million30.52 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable

CUTR, VRAY, AXGN, TMDX, and BLFS Headlines

SourceHeadline
The best 4K Blu-ray players for 2024The best 4K Blu-ray players for 2024
digitaltrends.com - March 24 at 6:22 PM
VRAY Jan 2025 2.000 callVRAY Jan 2025 2.000 call
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 putVRAY Jan 2025 0.500 put
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 callVRAY Jan 2025 0.500 call
finance.yahoo.com - March 16 at 12:50 AM
VRAY Jan 2025 3.000 putVRAY Jan 2025 3.000 put
finance.yahoo.com - March 16 at 12:50 AM
Creating the Scene with V-Ray for 3ds MaxCreating the Scene with V-Ray for 3ds Max
archdaily.com - March 2 at 1:34 PM
How to Supercharge Your SketchUp Renders With V-Ray Lights and MaterialsHow to Supercharge Your SketchUp Renders With V-Ray Lights and Materials
archdaily.com - February 26 at 6:18 PM
ViewRay Inc VRAYQViewRay Inc VRAYQ
morningstar.com - November 4 at 7:06 AM
NUBURU Appoints Brian Knaley as new CEONUBURU Appoints Brian Knaley as new CEO
benzinga.com - November 1 at 5:27 PM
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Lets Preserve ViewRay TechnologyOpen Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay Technology
tmcnet.com - October 19 at 8:02 AM
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global CompaniesLetter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
benzinga.com - October 17 at 1:37 PM
ViewRay Inc (6L9.BE)ViewRay Inc (6L9.BE)
ca.finance.yahoo.com - August 20 at 6:13 PM
B. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a NeutralB. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a Neutral
knoxdaily.com - July 24 at 3:24 PM
ViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeViewRay stock to be delisted from Nasdaq and moved to OTC Exchange
seekingalpha.com - July 21 at 6:20 PM
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
finance.yahoo.com - July 21 at 6:20 PM
Keeping an Eye on ViewRay Inc. (VRAY) After Insider Trading ActivityKeeping an Eye on ViewRay Inc. (VRAY) After Insider Trading Activity
knoxdaily.com - July 19 at 1:18 PM
Why ViewRay Stock Hit A New 52-Week Low TodayWhy ViewRay Stock Hit A New 52-Week Low Today
benzinga.com - July 18 at 8:33 PM
ViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsViewRay, Inc.: ViewRay Files Voluntary Chapter 11 Petitions
finanznachrichten.de - July 18 at 10:32 AM
Why ViewRay (VRAY) Stock Hit A New 52-Week Low TodayWhy ViewRay (VRAY) Stock Hit A New 52-Week Low Today
msn.com - July 17 at 1:15 PM
Why Is ViewRay (VRAY) Stock Down 69% Today?Why Is ViewRay (VRAY) Stock Down 69% Today?
investorplace.com - July 17 at 12:04 PM
ViewRay® Files Voluntary Chapter 11 PetitionsViewRay® Files Voluntary Chapter 11 Petitions
finance.yahoo.com - July 17 at 8:15 AM
ViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent daysViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent days
knoxdaily.com - July 12 at 5:59 PM
ViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - Sell
msn.com - July 7 at 9:16 AM
Analyzing ViewRay Inc. (VRAY) After Recent Trading ActivityAnalyzing ViewRay Inc. (VRAY) After Recent Trading Activity
knoxdaily.com - July 5 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
BioLife Solutions logo

BioLife Solutions

NASDAQ:BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Cutera logo

Cutera

NASDAQ:CUTR
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all body and skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and enlighten, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides excel HR, a hair removal solution for all skin types; and xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
ViewRay logo

ViewRay

NASDAQ:VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.